Guardant Health (GH) shares of the precision oncology name are staying strong relative to the market as it never even tested its rising 200 day EMA the past month and now back above its 21 and 55 MA’s as it nears a breakout from this 8-week narrow range. A close above 46 would trigger a move likely towards the 50 level which was the high in late January. The next VPOC resistance above there would come in at 54. GH still has the January $60 and $65 calls in open interest that bought in late February. Sales are projected to grow +20% through FY27.